Navigation Links
Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
Date:2/6/2013

tate cancer launch to build long-term value, and expect losses in the first and second quarters," said Dean Schorno, Chief Financial Officer of Genomic Health. 

Of note, non-GAAP basic net income per share, excluding stock compensation expense, is expected to be between $0.48 to $0.68.

Recent Business Highlights:

  • Presented data from six Oncotype DX studies from the United States and Europe at the San Antonio Breast Cancer Symposium (SABCS) in December across invasive breast cancer and DCIS (ductal carcinoma in situ), including a second comparison study highlighting clinically meaningful differences between the Oncotype DX Recurrence Score® and a commercially available prognostic 70-gene genomic classifier.
  • Announced that the full positive results from the large clinical validation study of the Oncotype DX prostate cancer test were accepted for oral presentation at the AUA Annual Meeting in early May.  Following the presentation of these positive results, the company plans to make the test available to physicians and patients in the second quarter of 2013.
  • Announced that the results from the second large colon cancer clinical validation study, which provided confirmation of the landmark QUASAR results, were accepted for publication in the Journal of Clinical Oncology.
  • Presented data in three presentations at the 2013 Gastrointestinal Cancers Symposium in January that reinforce the clinical utility and cost effectiveness of the Oncotype DX test in stage II colon cancer patients.
  • The December 2012 issue of Value in Health published results from a modeling study showing that the use of the Oncotype DX test in stage II colon cancer patients may lead to health care cost savings while imp
    '/>"/>

  • SOURCE Genomic Health, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Empire Genomics Chooses Funakoshi as Japan Distributor
    2. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
    3. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
    4. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
    5. Gentris Corporation Launches New Pharmacogenomics Services
    6. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
    7. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
    8. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
    9. Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
    10. Genomic Health to Present at the Canaccord Genuity Growth Conference
    11. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
    (Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
    (Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
    Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
    ... (NASDAQ: PRXL ), a leading global biopharmaceutical ... appointed several executives to its global team of ... in PAREXEL,s PACE™ (Peri-Approval Clinical Excellence) group. This team ... to prove the value of their products to multiple ...
    ... 2011 Biodesix today announced  that results from a ... phase III study, EGF30008, will be presented at the ... The purpose of the study was to evaluate the ... outcomes following treatment with either Femara ® or Femara ...
    Cached Medicine Technology:PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 2PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 3PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 4PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 5Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 2Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 3
    (Date:8/29/2015)... ... 2015 , ... Targeted therapies, made possible by a growing ... according to a newly published report. Surviving Mesothelioma has more on the findings ... The authors of the new paper focus on several types of targeted approaches ...
    (Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
    (Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
    (Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music ... Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best Drug ... underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best Drug ...
    (Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... On May ... Michigan, joined as sponsor of the “Music With A Mission” benefit concert in Mendon, ... the event was to raise money to support music education programs in the underfunded ...
    Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
    ... A Danish study had reported that children in their teens ... to the harsh glare of the sun. // In the ... researchers had asked 340 volunteers to wear a wristwatch that ... UVR doses. ,The volunteers of the study included ...
    ... and Japan have been able to identify a type ... //beings awake. By tracking the nerve cells in rats, ... neuron receives inhibitory signals during night that makes them ... a chemical called orexin that keeps the animal awake. ...
    ... that increased exposure to infections in early infancy, as ... of developing acute lymphoblastic leukemia. ,The study results ... UK of age 2 to 14 yrs without cancer ... acute lymphoblastic leukemia. Day care and social activities were ...
    ... Medical School said that intake of calcium supplements over ... people at risk of colon cancer.// ,Calcium ... pre-cancerous polyp formations in colon. Calcium has chemo protective ... ,The previous study was in a trial, which ...
    ... Athletes who drink water during long distance running events ... much water // is almost as bad for health ... says the study researchers of UT Southwestern Medical Center, ... long race may lead to a condition called hyponatremia. ...
    ... have found out that having green tea catechins for a ... in males.// ,Of the 32 people who were ... only one person developed the cancer. They all had been ... the property of green tea catechins or a component of ...
    Cached Medicine News:
    Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
    ... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
    Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
    ... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
    Medicine Products: